6,035 Shares in IQVIA Holdings Inc. $IQV Acquired by Redwood Investment Management LLC

Redwood Investment Management LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 6,035 shares of the medical research company’s stock, valued at approximately $1,166,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Financial Freedom LLC purchased a new stake in IQVIA during the first quarter valued at $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the 1st quarter valued at about $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA in the 4th quarter worth approximately $27,000. Compass Financial Management LLC bought a new stake in IQVIA during the second quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter valued at approximately $27,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $261.57 on Thursday. The stock has a market cap of $43.05 billion, a PE ratio of 32.45, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $262.51. The firm has a fifty day moving average price of $218.41 and a 200-day moving average price of $188.59. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IQV. BMO Capital Markets boosted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Stifel Nicolaus raised their target price on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Robert W. Baird lifted their target price on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Barclays reissued an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.